EXTON, Pa., May 9, 2013 /PRNewswire/ -- ViroPharma
Incorporated (Nasdaq: VPHM) today announced that Robert Doody, director of investor relations,
will present at the 2013 Bank of America Merrill Lynch Healthcare
Conference at 11:20 AM PT
(2:20 PM ET) on Tuesday, May 14, 2013. The conference is
being held at the Encore at the Wynn Hotel in Las Vegas, NV.
ViroPharma also announced that Charles
Rowland, vice president and chief financial officer of
ViroPharma, will present at the Deutsche Bank 38th Annual
Healthcare Conference at 9:20 AM ET
on Wednesday, May 29, 2013. The
conference is being held at the Westin Boston Waterfront Hotel.
ViroPharma's presentations will be webcast live for investors
through www.viropharma.com and available for a period of 14
days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated
is an international biopharmaceutical company committed to
developing and commercializing novel solutions for physician
specialists to address unmet medical needs of patients living with
diseases that have few if any clinical therapeutic
options. ViroPharma is developing a portfolio of therapeutics
for rare and Orphan diseases including C1 esterase inhibitor
deficiency, cytomegalovirus (CMV), Friedreich's Ataxia,
eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal
is to provide rewarding careers to employees, to create new
standards of care in the way serious diseases are treated, and to
build international partnerships with the patients, advocates, and
health care professionals we serve. ViroPharma's commercial
products address diseases including hereditary angioedema (HAE),
seizures in children and adolescents, adrenal insufficiency and
C. difficile-associated diarrhea (CDAD). For full U.S.
prescribing information on our products, please download the
package inserts at http://www.viropharma.com/Products.aspx; the
prescribing information for other countries can be found at
www.viropharma.com.
ViroPharma routinely posts information, including press
releases, which may be important to investors in the investor
relations and media sections of our company's web site,
www.viropharma.com. The company encourages investors to consult
these sections for more information on ViroPharma and our
business.
SOURCE ViroPharma Incorporated